HOOKIPA Pharma Inc. (HOOK)
- Previous Close
0.7649 - Open
0.7500 - Bid 0.7074 x 400
- Ask 0.7670 x 100
- Day's Range
0.7314 - 0.7999 - 52 Week Range
0.4100 - 2.0500 - Volume
415,187 - Avg. Volume
543,077 - Market Cap (intraday)
72.53M - Beta (5Y Monthly) 1.02
- PE Ratio (TTM)
-- - EPS (TTM)
-0.8600 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.70
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-200 for the treatment of pembrolizumab which is in Phase 2 of clinical trial; HB-700, a preclinical development for treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers. Its lead product candidates are HB-400 for the treatment of Hepatitis B which is in Phase I of clinical trial and HB-500 for the treatment of HIV which is in Phase I of clinical trial. The company's preclinical stage products include HB-300 program for prostate cancer. It has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.
www.hookipapharma.comRecent News: HOOK
Performance Overview: HOOK
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HOOK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HOOK
Valuation Measures
Market Cap
75.45M
Enterprise Value
-35.09M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.58
Price/Book (mrq)
0.84
Enterprise Value/Revenue
-1.74
Enterprise Value/EBITDA
0.45
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-32.00%
Return on Equity (ttm)
-84.81%
Revenue (ttm)
20.13M
Net Income Avi to Common (ttm)
-81.58M
Diluted EPS (ttm)
-0.8600
Balance Sheet and Cash Flow
Total Cash (mrq)
117.1M
Total Debt/Equity (mrq)
7.30%
Levered Free Cash Flow (ttm)
-39.97M